La Jolla Pharmaceutical Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.4M
Doctors Paid
8,547
Transactions
18,917
2024 Total
$705,902
Payment Breakdown by Category
Research$2.5M (38.6%)
Food & Beverage$730,569 (11.4%)
Consulting$247,937 (3.9%)
Travel$189,516 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 350 | 38.6% |
| Honoraria | $1.5M | 559 | 23.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 352 | 18.0% |
| Food and Beverage | $730,569 | 16,591 | 11.4% |
| Consulting Fee | $247,937 | 106 | 3.9% |
| Travel and Lodging | $189,516 | 677 | 3.0% |
| Space rental or facility fees (teaching hospital only) | $81,980 | 69 | 1.3% |
| Education | $33,362 | 211 | 0.5% |
| Grant | $20,000 | 2 | 0.3% |
Payments by Type
General
$3.9M
18,567 transactions
Research
$2.5M
350 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2, MULTI-CENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WITH LJPC-401 FOR THE TREATMENT OF IRON OVERLOAD IN ADULT PATIENTS WITH HEREDITARY HEMOCHROMATOSIS | $1.3M | 0 | 267 |
| A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia | $419,361 | 0 | 4 |
| A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY WITH LJPC-401 FOR THE TREATMENT OF MYOCARDIAL IRON OVERLOAD IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA | $147,341 | 0 | 25 |
| A National Surveillance Program to Evaluate the In Vitro Potency of Standard-of-Care Antibiotics against Contemporary Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients | $129,100 | 0 | 4 |
| A STUDY OF LJPC-501 IN PEDIATRIC PATIENTS WITH HYPOTENSION | $102,103 | 0 | 10 |
| Angiotensin-II in Sepsis: Immune scRNA Seq Proposal Summary | $99,000 | 0 | 1 |
| EXPANDED ACCESS FOR LJPC-501 | $55,592 | 0 | 16 |
| Ex vivo modeling and simulation to guide Sulbactum Durlobactam dosing | $39,875 | 0 | 2 |
| Development and validation for the measurement of sulbactam and durlobactam in plasma free filtrate (PFF), effluent, and plasma via LC-MS/MS | $30,000 | 0 | 1 |
| Y site compatibility with sulbactam-durlobactam | $25,884 | 0 | 1 |
| Physical Compatibility with Sulbactam Durlobactam | $25,883 | 0 | 1 |
| In vitro static time kills with cefepime | $23,518 | 0 | 2 |
| EFFECT OF CARDIOPULMONARY BYPASS ON SERUM BIOMARKERS OF IRON | $16,296 | 0 | 7 |
| Angiotensin II as a first-line vasopressor for distributive shock for heart transplant and left ventricular assist device implantation recipients: A Pilot Study | $13,257 | 0 | 1 |
| The Effect of Angiotensin II on Vasoplegic Shock | $12,617 | 0 | 1 |
| Medication Use Evaluation with GIAPREZA for Patients with distributive shock including COVID-19 | $9,996 | 0 | 4 |
| Angiotensin II in Liver Transplantation (ANGLT-1): A Pilot Randomized Controlled Trial | $7,116 | 0 | 1 |
| DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) pilot: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock, a randomized controlled pilot trial | $1,920 | 0 | 1 |
| A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis | $909.70 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Kevin Finkel, M.d, M.D | Internal Medicine | Houston, TX | $10,705 | $0 |
| Mr. Martin Gnoni, Md, MD | Student in an Organized Health Care Education/Training Program | Louisville, KY | $10,461 | $0 |
| Dr. Marina Kremyanskaya, M.d, M.D | Medical Oncology | New York, NY | $10,401 | $0 |
| Dr. Matthew Wallenstein, M.d, M.D | Obstetrics & Gynecology | Palo Alto, CA | $10,347 | $0 |
| Dr. Timothy Albertson, Md, Phd, Mph, MD, PHD, MPH | Medical Toxicology | Sacramento, CA | $9,888 | $0 |
| Dr. Salim Surani, M.d, M.D | Pulmonary Disease | Corpus Christi, TX | $9,818 | $0 |
| Dr. Ali Seifi, Md, MD | Neurocritical Care | San Antonio, TX | $9,799 | $0 |
| Dr. James Tumlin, M.d, M.D | Nephrology | Lawrenceville, GA | $9,437 | $0 |
| Dr. Ronald Hoffman, M.d, M.D | Hematology & Oncology | New York, NY | $9,192 | $0 |
| Dr. Michael Jopling, M.d, M.D | Pain Medicine | Westerville, OH | $8,799 | $0 |
| Jinesh Mehta, M.d, M.D | Pulmonary Disease | Weston, FL | $8,755 | $0 |
| Hung Nguyen, M.d, M.D | Critical Care Medicine | Loma Linda, CA | $8,595 | $0 |
| Richard Wunderink, Md, MD | Pulmonary Disease | Chicago, IL | $8,518 | $0 |
| Dwight Bailey, Do, DO | Pediatrics | Charlotte, NC | $8,444 | $0 |
| Dr. Amar Safdar, M.d, M.D | Infectious Disease | Houston, TX | $8,260 | $0 |
| Mr. Javier Perez-Fernandez | Critical Care Medicine | Miami, FL | $7,806 | $0 |
| Dr. Akshay Shah, M.d, M.D | Specialist | Bloomfield Hills, MI | $7,796 | $0 |
| Ruben Mesa, Md, MD | Hematology & Oncology | Charlotte, NC | $7,397 | $0 |
| Dr. Priyank Desai, M.d, M.D | Critical Care Medicine | Rocky Mount, NC | $7,027 | $0 |
| Joseph Varon, Md, MD | Internal Medicine | Houston, TX | $6,968 | $0 |
| Moshe Talpaz, Md, MD | Internal Medicine | Ann Arbor, MI | $6,831 | $0 |
| Kelly Coon, M.d, M.D | Internal Medicine | Scottsbluff, NE | $6,735 | $0 |
| Edward Johnson, Md, MD | Infectious Disease | Fort Myers, FL | $6,725 | $0 |
| Deepthi Jayasekara, Md, MD | Infectious Disease | Claremont, CA | $6,330 | $0 |
| V Reddy, Md, MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Nashville, TN | $6,183 | $0 |
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company has made $6.4M in payments to 8,547 healthcare providers, recorded across 18,917 transactions in the CMS Open Payments database. In 2024, the company paid $705,902. The top product by payment volume is GIAPREZA ($3.9M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Critical Care Medicine ($900,051 to 661 doctors).
Payment categories include: Food & Beverage ($730,569), Consulting ($247,937), Research ($2.5M), Travel & Lodging ($189,516).
La Jolla Pharmaceutical Company is associated with 3 products in the CMS Open Payments database.